Skip to main content
. 2019 Apr 5;9:5692. doi: 10.1038/s41598-019-42245-3

Figure 5.

Figure 5

Mechanism of PCC0208027 anti-tumor activity in NSCLC tumor xenograft models. Ki67 and p-EGFR (or p-HER2) positive cells was observed in the tumor tissue (brown-colored objects) (200×). (a) PCC0208027, erlotinib, and osimertinib strongly decreased the number of p-EGFR and Ki67 positive cells in tumor tissues in comparison to the control group in HCC827 xenograft model. (b) PCC0208027 and osimertinib strongly decreased the number of p-EGFR and Ki67 positive cells in tumor tissues in NCI-H1975 xenograft model. (c) PCC0208027 significantly reduce the number of p-HER2 and Ki67 positive cells in tumor tissues in comparison to the control group in Calu-3 xenograft model. Columns, mean; bars, ***P < 0.001, compared to the control group.